Detalhe da pesquisa
1.
Property activity refinement of 2-anilino 4-amino substituted quinazolines as antimalarials with fast acting asexual parasite activity.
Bioorg Chem
; 117: 105359, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34689083
2.
Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity.
Bioorg Chem
; 115: 105244, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452759
3.
Generation of monoclonal antibodies against native viral proteins using antigen-expressing mammalian cells for mouse immunization.
BMC Biotechnol
; 16(1): 83, 2016 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27876044
4.
Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA.
Malar J
; 15: 161, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26979066
5.
Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen.
J Immunol
; 188(12): 6225-37, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22593616
6.
The essential malaria protein PfCyRPA targets glycans to invade erythrocytes.
Cell Rep
; 43(4): 114012, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573856
7.
7-N-Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome bc1 Complex.
ACS Infect Dis
; 9(3): 668-691, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853190
8.
Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.
J Med Chem
; 66(5): 3540-3565, 2023 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36812492
9.
Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.
ChemMedChem
; 17(18): e202200306, 2022 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35906744
10.
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Structure
; 30(7): 947-961.e6, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460613
11.
The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.
ACS Med Chem Lett
; 13(11): 1745-1754, 2022 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385924
12.
Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362.
J Med Chem
; 65(20): 14121-14143, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36216349
13.
Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models.
NPJ Vaccines
; 5: 9, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32025340
14.
Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
Cell Host Microbe
; 27(4): 642-658.e12, 2020 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32109369
15.
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody.
Elife
; 62017 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28195038